This study aims to evaluate the efficacy of dual therapy compared with bismuth-containing quadruple therapy as first-line treatment for Helicobacter Pylori eradication, as well as the safety and economic benefits.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
393
Potassium-competitive acid blocker
Proton pump inhibitor
Antibiotic for H. pylori eradication
Second Affiliated Hospital of Zhejiang University, School of Medicine
Hangzhou, Zhejiang, China
RECRUITINGHelicobacter pylori Eradication Rate
Helicobacter pylori Eradication will be determined by ¹³C-urea breath test six to eight weeks after completion of the medication. The eradication rates will be evaluated by intention-to-treat (ITT) and per-protocol (PP) analysis.
Time frame: Six to eight weeks after completion of the medication
Rate of Adverse Drug Reaction(ADR)
Adverse drug reactions are classified into six types (with mnemonics): dose-related (Augmented), non-dose-related (Bizarre), dose-related and time-related (Chronic), time-related (Delayed), withdrawal (End of use), and failure of therapy (Failure).
Time frame: Within 7 days after completion of therapy
Compliance Rate
Compliance was defined as poor when they had taken less than 80% of the total medication.
Time frame: Within 7 days after completion of therapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Antibiotic for H. pylori eradication
Gastric mucosal protective drug with anti-H. pylori effect